Clinipace Worldwide to manage Prometheus oncology program

Wednesday, July 18, 2012 01:29 PM

Morrisville, N.C.-based Clinipace Worldwide, a global digital research organization (dCRO), said Prometheus Laboratories, a specialty pharmaceutical and diagnostic company, has awarded it an Oncology Program.  Immediate plans are commencing for two metastatic melanoma studies.  

Initially, Clinipace Worldwide will manage a study of Proleukin (aldesleukin) and Vemurafenib therapy in patients with metastatic melanoma (mM). This study is expected to include up to 30 sites in the U.S. with a sample size of 135 patients in the naïve patient arm.  The study is expected to enroll patients over an 18-month period, with additional follow-up of two years required.  Proleukin remains the only therapy to deliver durable remissions in metastatic renal cell carcinoma and metastatic melanoma.

A second study will compare the sequence of high-dose Proleukin (aldesleukin) and 3mg/kg Ipilimumab immunotherapy in patients with metastatic melanoma.  The study will enroll up to 120 patients at approximately 15 study sites around the U.S. 

“Patient enrollment is one of the biggest challenges we face when starting an oncology trial; thus, it was critically important for us to team with a CRO we felt could provide oncology expertise along with a robust electronic data management platform,” said Todd Butler, director of clinical operations for Prometheus. “We will be able to monitor our studies to ensure they are on track right from the start; specifically, the number of patients enrolled at each of our sites, as well as factors that impact enrollment and protocol compliance.  With the ability to monitor these critical areas in real-time, the study teams will have the ability to adjust patient enrollment strategies with improved data quality.”

“Embracing technology can be on one of the most powerful and cost-effective ways to enhance the success of a clinical trial,” said Jeff Williams, CEO of Clinipace Worldwide.  “By partnering with a digital CRO, you can be assured of safer trials and higher quality data delivered more efficiently and cost-effectively.”

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs